scholarly journals Association Between Family Factors and Illicit Polysubstance Use Amongst Methadone Maintenance Patients with Opioid Use Disorder

2018 ◽  
Vol 7 (4) ◽  
Author(s):  
Hamnah Shahid ◽  
Meha Bhatt ◽  
Nitika Sanger ◽  
Laura Zielinski ◽  
Candice Luo ◽  
...  
Keyword(s):  
Methadone Maintenance ◽  
Opioid Use Disorder ◽  
Family Factors ◽  
Opioid Use ◽  
Polysubstance Use

scholarly journals Psychosis and Comorbid Opioid Use Disorder: Characteristics and Outcomes in Opioid Substitution Therapy

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Rachel Lamont ◽  
Tea Rosic ◽  
Nitika Sanger ◽  
Zainab Samaan
Keyword(s):  
Psychotic Disorder ◽  
Psychotic Disorders ◽  
Methadone Maintenance ◽  
Opioid Use Disorder ◽  
Mood Stabilizers ◽  
Opioid Use ◽  
Opioid Substitution Therapy ◽  
Group Status ◽  
Urine Drug ◽  
Retention In Treatment

Abstract Background and Objectives Substance use disorders are highly prevalent among individuals with psychotic disorders and are associated with negative outcomes. This study aims to explore differences in characteristics and treatment outcomes for individuals with psychotic disorders when compared with individuals with other nonpsychotic psychiatric disorders enrolled in treatment for opioid use disorder (OUD). Methods Data were collected from a prospective cohort study of 415 individuals enrolled in outpatient methadone maintenance treatment (MMT). Psychiatric comorbidity was assessed using the Mini-International Neuropsychiatric Interview. Participants were followed for 12 months. Participant characteristics associated with having a psychotic disorder versus another nonpsychotic psychiatric disorder were explored by logistic regression analysis. Results Altogether, 37 individuals (9%) with a psychotic disorder were identified. Having a psychotic disorder was associated with less opioid-positive urine drug screens (odds ratio [OR] = 0.97, 95% confidence interval [CI] = 0.95, 0.99, P = .046). Twelve-month retention in treatment was not associated with psychotic disorder group status (OR = 0.73, 95% CI = 0.3, 1.77, P = .485). Participants with psychotic disorders were more likely to be prescribed antidepressants (OR = 2.12, 95% CI = 1.06, 4.22, P = .033), antipsychotics (OR = 3.57, 95% CI = 1.74, 7.32, P = .001), mood stabilizers (OR = 6.61, 95% CI = 1.51, 28.97, P = .012), and benzodiazepines (OR = 2.22, 95% CI = 1.11, 4.43, P = .024). Discussion and Conclusions This study contributes to the sparse literature on outcomes of individuals with psychotic disorders and OUD-receiving MMT. Rates of retention in treatment and opioid use are encouraging and contrast to the widely held belief that these individuals do more poorly in treatment. Higher rates of coprescription of sedating and QTc-prolonging medications in this group may pose unique safety concerns.

scholarly journals The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment

BJPsych Open ◽  
2019 ◽  
Vol 5 (6) ◽  
Author(s):  
Ieta Shams ◽  
Nitika Sanger ◽  
Meha Bhatt ◽  
Tea Rosic ◽  
Candice Luo ◽  
...  
Keyword(s):  
Anxiety Disorders ◽  
Methadone Maintenance Treatment ◽  
Odds Ratio ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Current Treatment ◽  
Opioid Use Disorder ◽  
Cannabis Use ◽  
Health Conditions ◽  
Opioid Use

Background Cannabis is the most commonly used substance among patients in methadone maintenance treatment (MMT) for opioid use disorder. Current treatment programmes neither screen nor manage cannabis use. The recent legalisation of cannabis in Canada incites consideration into how this may affect the current opioid crisis. Aims Investigate the health status of cannabis users in MMT. Method Patients were recruited from addiction clinics in Ontario, Canada. Regression analyses were used to assess the association between adverse health conditions and cannabis use. Further analyses were used to assess sex differences and heaviness of cannabis use. Results We included 672 patients (49.9% cannabis users). Cannabis users were more likely to consume alcohol (odds ratio 1.46, 95% CI 1.04–2.06, P = 0.029) and have anxiety disorders (odds ratio 1.75, 95% CI 1.02–3.02, P = 0.043), but were less likely to use heroin (odds ratio 0.45, 95% CI 0.24–0.86, P = 0.016). There was no association between cannabis use and pain (odds ratio 0.98, 95% CI 0.94–1.03, P = 0.463). A significant association was seen between alcohol and cannabis use in women (odds ratio 1.79, 95% CI 1.06–3.02, P = 0.028), and anxiety disorders and cannabis use in men (odds ratio 2.59, 95% CI 1.21–5.53, P = 0.014). Heaviness of cannabis use was not associated with health outcomes. Conclusions Our results suggest that cannabis use is common and associated with psychiatric comorbidities and substance use among patients in MMT, advocating for screening of cannabis use in this population. Declaration of interest None.

scholarly journals Adjuvant laser meridian massage in men with opioid use disorder on methadone maintenance treatment

Medicine ◽  
2019 ◽  
Vol 98 (39) ◽  
pp. e17319 ◽  
Author(s):  
Wen-Long Hu ◽  
Meng-Chang Tsai ◽  
Chun-En Kuo ◽  
Chun-Ting Liu ◽  
Szu-Ying Wu ◽  
...  
Keyword(s):  
Methadone Maintenance Treatment ◽  
Maintenance Treatment ◽  
Methadone Maintenance ◽  
Opioid Use Disorder ◽  
Opioid Use

scholarly journals Decreased Level of Blood MicroRNA-133b in Men with Opioid Use Disorder on Methadone Maintenance Therapy

2019 ◽  
Vol 8 (8) ◽  
pp. 1105
Author(s):  
Hsu ◽  
Huang ◽  
Tsai
Keyword(s):  
Animal Studies ◽  
Methadone Maintenance ◽  
Opioid Use Disorder ◽  
Methadone Maintenance Therapy ◽  
Healthy Controls ◽  
Opioid Use ◽  
Ribonucleic Acids ◽  
Methadone Dosage ◽  
The Difference ◽  
Serum Micrornas

Although previous animal studies have indicated that certain micro ribonucleic acids (microRNAs) play a part in the pathway of opioid addiction, whether such findings extend to human models is yet unknown. This study aims to investigate the important microRNA expressions in patients with opioid use disorder (OUD) on methadone maintenance treatment (MMT) compared to healthy controls and analyze the correlation between microRNAs and opioid characteristics among the patients. We recruited 50 patients and 25 controls, and both groups were matched regarding gender, age, and body mass index. Serum microRNAs (miR-133b, miR-23b, miR-190, miR-206, miR-210, and miR-21) were measured. The age of OUD onset, duration of MMT participation, and recent daily methadone dosage were considered the opioid characteristics. We adopted the t-test to compare the difference between patients and controls and Pearson's correlation to evaluate the association between microRNAs and opioid profiles. Only the level of miR-133b in OUD patients on MMT was significantly lower than that in healthy controls. We did not detect differences of any other microRNA expressions between the two groups. Furthermore, we found no evidence to support the association between microRNAs and opioid characteristics. This study indicates that miR-133b values may be decreased in OUD patients on MMT.

Sign in / Sign up

Export Citation Format

Share Document